Search for retatrutide Phase 3 results and you will be told the drug produced 30% weight loss. Search a little differently and you will be told 22.6%. Somewhere else, 20.8%.
All of those numbers are real. None of them is wrong. They come from different trials, in different populations, measured at different weeks.
The reason this matters is that a figure quoted without its trial is close to meaningless, and almost every summary of this data drops the trial and keeps the biggest number. Here is the full set, and what separates them.
Investigational drug, research-use material
Retatrutide is an investigational pharmaceutical developed by Eli Lilly. It is not approved by any regulator. Every clinical figure on this page describes a drug product administered to trial participants under clinical supervision, and none of it describes or predicts the behaviour of research-grade reference material. Validated Peptides supplies compounds for laboratory research only, not for human consumption.
The short version
Retatrutide is a triple hormone receptor agonist. It activates the GIP, GLP-1 and glucagon receptors, which is one more target than tirzepatide and two more than semaglutide.
The TRIUMPH program is four Phase 3 trials covering more than 5,800 participants, built as a basket design so that obstructive sleep apnea and knee osteoarthritis protocols sit inside the weight management trials. Three weight readouts have been announced. A separate Phase 3 program, TRANSCEND, covers type 2 diabetes, and its first trial has been published in The Lancet.
Across those four readouts, average weight reduction on the highest dose ranged from 15.3% to 28.3%, with a 104-week extension reaching 30.3% in a selected subgroup.
Five numbers, one drug
| Trial | Population | n | Weeks | Top dose result | Placebo |
|---|---|---|---|---|---|
| TRIUMPH-1 | Obesity | 2,339 | 80 | −28.3% | −2.2% |
| TRIUMPH-1 extension | Baseline BMI ≥35, week-80 completers | 532 | 104 | −30.3% | not applicable |
| TRIUMPH-2 | Type 2 diabetes with obesity or overweight | 1,152 | 80 | −20.8% | −4.0% |
| TRIUMPH-3 | Severe obesity with established cardiovascular disease | 1,949 | 80 | −22.6% | −3.2% |
| TRANSCEND-T2D-1 | Type 2 diabetes, monotherapy | 537 | 40 | −15.3% | −2.6% |
All figures are the highest dose arm the trial reported, which was 12 mg once weekly in every case. TRIUMPH-1 also reported 19.0% on 4 mg and 25.9% on 9 mg, so the dose response within a single trial is itself substantial.
Notice the placebo arms as well. They range from 2.2% to 4.0%. Placebo response differs by population too, which is part of why cross-trial comparison is a trap.
Why the same drug produced different results
Two variables explain most of the spread: who was enrolled, and for how long.
The clearest signal is type 2 diabetes. TRIUMPH-1, in adults with obesity, reached 28.3%. TRIUMPH-2, in adults with type 2 diabetes, reached 20.8% over the same 80 weeks at the same dose. That is a gap of nearly eight percentage points from the diagnosis alone.
This is not specific to retatrutide. Reduced weight response in people with type 2 diabetes is a reproducible finding across the entire incretin class, seen with semaglutide and tirzepatide before it. The prevailing explanations involve differences in insulin dynamics and the metabolic adaptations that accompany established diabetes. Whatever the mechanism, it is consistent enough that comparing a diabetes trial against an obesity trial tells you more about the enrolment criteria than about the molecule.
Duration is the second variable. TRANSCEND-T2D-1 ran 40 weeks and reached 15.3%. TRIUMPH-2 ran 80 weeks in a broadly similar population and reached 20.8%. Weight curves in these trials are still descending when the trial ends, so a shorter trial reports a smaller number for reasons that have nothing to do with efficacy.
Think of it like reading a race split. A runner at the 10 km mark is not slower than a runner at the finish line. You are looking at two different points on the same curve.
The 30.3% figure deserves an asterisk
This is the number most often repeated, and it carries the most conditions.
It comes from a 104-week extension of TRIUMPH-1 rather than the main analysis. The extension population was 532 participants, down from 2,339, and entry was restricted in two ways. Participants needed a baseline BMI of at least 35, and they needed to have completed week 80 without discontinuing. Those who continued were then escalated to a maximum tolerated dose.
Why a completers-only extension reads high
Selecting participants who lasted 80 weeks without stopping removes, by construction, everyone who could not tolerate the drug or was not responding well enough to continue. The remaining group is enriched for people who both tolerated the compound and were doing well on it. This is a normal and disclosed feature of extension studies, and it is exactly why an extension result should not be quoted as though it were the trial result.
The honest way to state it: retatrutide produced an average 28.3% reduction at 80 weeks in the full TRIUMPH-1 population on 12 mg, and a selected subgroup carried to 104 weeks averaged 30.3%. Both are worth knowing. Only one of them is the headline result.
One further figure from TRIUMPH-1 is arguably more informative than either: 45.3% of participants on 12 mg achieved at least a 30% reduction, against 0.5% on placebo. Averages hide distribution, and that split says more about the range of individual response than any mean does.
Only one of these has been peer reviewed
This distinction gets lost almost everywhere, and it is the most important caveat on the page.
The TRIUMPH-1, TRIUMPH-2 and TRIUMPH-3 figures come from Eli Lilly topline press releases. Topline announcements are real data released by the sponsor, but they are summaries. They have not been through peer review, the full analyses are not public, and the detail that lets an independent reader evaluate the result is not yet available.
TRANSCEND-T2D-1 is different. It was published in The Lancet in June 2026 with the full method, the estimand definitions, confidence intervals and the adverse event tables. That is the one trial in this set an outside reader can actually interrogate.
None of this suggests the TRIUMPH numbers are wrong. It means they are provisional in a way the coverage rarely conveys. Phase 2 results for this compound were published in the New England Journal of Medicine and The Lancet, so full Phase 3 publications should be expected in time.
What the third receptor actually adds
Semaglutide targets the GLP-1 receptor. Tirzepatide targets GLP-1 and GIP. Retatrutide adds the glucagon receptor to those two.
Adding glucagon agonism to a weight-loss drug sounds contradictory at first, since glucagon raises blood glucose. The rationale is that glucagon receptor activation also increases energy expenditure and drives hepatic fat mobilisation. Pairing it with two incretin receptor agonists is intended to offset the glycemic effect while keeping the metabolic one.
A rough analogy: the GLP-1 and GIP components work mostly on the intake side of the energy equation, and the glucagon component pushes on the expenditure side. Most of the class has only ever pulled one of those levers.
Whether the third receptor is responsible for the larger weight figures is not something these trials were designed to answer. None of them compares retatrutide head to head against tirzepatide or semaglutide, so any claim that one is stronger than another rests on cross-trial comparison, which is the same error this article opened with. The mechanistic case is reasonable. The comparative case has not been run.
The part the summaries leave out
Weight figures travel widely. Tolerability data does not.
In TRIUMPH-1, on the 12 mg arm against placebo: nausea 42.4% versus 14.8%, diarrhea 32.0% versus 13.5%, constipation 26.1% versus 10.9%, vomiting 25.3% versus 4.8%. Discontinuation due to adverse events was 11.3% versus 4.9%.
So roughly one in nine participants on the top dose stopped because of side effects. In TRIUMPH-3, in the cardiovascular disease population, discontinuation ran 9.8% to 13.5% across arms. In TRANSCEND-T2D-1, at a lower duration, discontinuations attributed to adverse events were 2% to 5%, with no severe hypoglycemia reported and two deaths, both in the 4 mg group and both assessed as unrelated to the study drug.
The adverse event profile is described as consistent with other molecules carrying GLP-1 receptor agonist activity. That is the expected pattern for the class, and it is part of the result rather than a footnote to it.
Where this sits with the FDA
Retatrutide is not approved. Not in the United States, not anywhere.
Eli Lilly has stated it plans to submit retatrutide for US approval in Q1 2027, with further Phase 3 readouts from the TRIUMPH program expected before then, including maintenance dosing strategies and the obstructive sleep apnea and knee osteoarthritis endpoints nested in the basket design.
Until a submission is filed and reviewed, every figure on this page is data from a development program rather than a characterised medicine. That gap is not a formality. It is where dosing, labelling, contraindications and long-term safety get established.
What this data does and does not say about research material
Retatrutide is also studied outside Lilly's program, as a reference compound in laboratory work on incretin receptor signalling, and that is the context in which it appears in the research supply market.
The distinction to hold onto is that the trial data above describes a pharmaceutical product, manufactured under pharmaceutical controls and administered to people under clinical supervision. It says nothing about the identity, purity or behaviour of research-grade material, and it is not a basis for any expectation about it. Validated Peptides supplies GLP-3Reta as reference material for laboratory research. It is not a drug product, it is not the investigational product used in these trials, and it is not for human consumption.
What does transfer between the two contexts is the question of whether the compound in a vial is what the label says. For a peptide of this size, identity confirmation by mass spectrometry and purity by HPLC are the relevant checks, and a certificate is only useful if it can be traced to the laboratory that issued it. Our reports are published on the Certificate of Analysis page, and two companion articles cover the mechanics: how to actually read a peptide COA and how to verify one against the issuing lab.
Common questions
What were the retatrutide TRIUMPH Phase 3 results?
TRIUMPH-1, in adults with obesity, reported average reductions of 19.0%, 25.9% and 28.3% on the 4 mg, 9 mg and 12 mg arms at 80 weeks against 2.2% on placebo. TRIUMPH-2, in adults with type 2 diabetes, reported 12.7%, 19.1% and 20.8% with A1C reductions up to 1.6%. TRIUMPH-3, in adults with severe obesity and established cardiovascular disease, reported 21.6% on 9 mg and 22.6% on 12 mg.
Did retatrutide really produce 30% weight loss?
In a 104-week extension, yes, in a selected subgroup. That extension enrolled 532 participants with a baseline BMI of at least 35 who had completed week 80 without discontinuing, then escalated them to a maximum tolerated dose. The headline TRIUMPH-1 result at 80 weeks in the full population is 28.3%.
Why do published numbers vary so much?
Because they come from different trials. Population is the dominant variable, particularly the presence of type 2 diabetes, and trial duration is the second. A weight figure is only interpretable alongside the trial, the dose arm and the week it was measured.
Is retatrutide FDA approved?
No. It is investigational and not approved by any regulator. Eli Lilly has said it plans to submit for US approval in Q1 2027.
How does it differ from tirzepatide?
Tirzepatide is a dual GIP and GLP-1 receptor agonist. Retatrutide adds glucagon receptor agonism as a third target, which is associated with increased energy expenditure and effects on liver fat. No head-to-head trial between the two has been reported, so the two cannot be ranked against each other from the data available.
Has any of this been peer reviewed?
TRANSCEND-T2D-1 was published in The Lancet in June 2026. The three TRIUMPH weight readouts described here are company topline announcements and have not yet appeared as full publications.
References
Trial figures are taken from Eli Lilly's own announcements and from the peer-reviewed literature, not from secondary coverage. Where the two would differ, the primary source governs.
- Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1, NCT05929066). Company announcement
- Eli Lilly and Company. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials (TRIUMPH-2, NCT05929079; TRIUMPH-3, NCT05882045). Company announcement
- Bajaj HS, Welch M, Shah P, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026;407(10546):2402-2413. PMID 42250575
- Giblin K, Kaplan LM, Somers VK, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: rationale and design of the TRIUMPH registrational clinical trials. Diabetes Obes Metab. 2026;28(1):83-93. PMID 41090431
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med. 2023. PMID 37366315
- Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial. Lancet. 2023. PMID 37385280
- Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30. PMID 38858523
- Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol. 2025. PMID 40609566